Obstetrics/Gynecology General
RSSArticles
-
Generic Pre-Exposure Prophylaxis Set to Debut
Pre-exposure prophylaxis (PrEP), which consists of the anti-HIV drugs emtricitabine and tenofovir disoproxil fumarate (TDF/FTC, brand name Truvada), is recommended as a first-line resource in HIV prevention. A generic version of the drug combination is set to be released in 2020, which could expand access to PrEP in the United States.
-
Drug Studied for Treatment of Fibroid-Associated Bleeding
Elagolix, a gonadotropin-releasing hormone antagonist currently used in the treatment of endometriosis pain, is now being studied for treatment of uterine fibroids and heavy menstrual bleeding in women. The drug was approved by the FDA in July 2018 for the treatment of moderate to severe endometriosis pain.
-
Expanding Intrauterine Contraceptive Choices: Science Seeks Options
The copper T 380A intrauterine device (IUD), developed almost 50 years ago, was introduced in the United States in 1988. It is an extremely effective form of birth control. Researchers are conducting a clinical trial comparing the device with a newer, smaller copper IUD not sold in the United States.
-
Are We Doing Too Many Unnecessary Pelvic Exams and Pap Tests in Young Women?
In this cross-sectional national survey, the authors estimated that 23% of women aged 15 to 20 years had received a bimanual pelvic exam, of which half (54%) were deemed potentially unnecessary, and 19% of the population received a Pap test, of which 72% were potentially unnecessary.
-
Knowledge of Pelvic Floor Disorders Among Pregnant and Postpartum Women
Pregnant and postpartum patients lack knowledge about urinary incontinence and prolapse.
-
Baby-Friendly Policies May Be Ineffective in Improving Breastfeeding Outcomes in the United States
Data analysis from the 2018 Centers for Disease Control and Prevention Breastfeeding Report Card failed to show improvements in breastfeeding outcomes in Baby-Friendly facilities over statewide breastfeeding initiation programs.
-
More Young Adults Receiving HPV Vaccination, but There Is Room for Improvement
Results of a new report indicate that the percentage of adults ages 18-26 years who received one or more doses of human papillomavirus (HPV) vaccine nearly doubled between 2013 and 2018. The percentage of adults in the same age category who received the recommended number of doses of HPV vaccine increased from 13.8% to 21.5%.
-
New Congressional Funding for STD Programs: Is It Enough?
Congress recently increased federal funding for sexually transmitted disease (STD) prevention for the first time since 2003, with a $3.51 million addition in base funding to the CDC’s STD prevention programs. But is the funding enough to fully address the rise in national STD rates?
-
Consensus Position Statement on the Use of Testosterone in Women
Clinicians lack clearly established guidance and indications for testosterone therapy for women, which has led to considerable variation in practice patterns. The absence of clear indications and approved products for women has resulted in the use of compounded therapies or off-label prescription of testosterone formulations approved for men.
-
Check Your Practice: Are Unnecessary Pelvic Exams and Pap Tests Being Performed?
While pelvic examinations and cervical cancer screenings are no longer recommended for most young women under age 21 years during routine health visits, results from a new national study indicate that millions of women are undergoing these tests unnecessarily.